Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model
Trial details
- Registry ID
- NCT07503405
- Drugs studied
- Influenza A/France/759/2021 (H1N1) virus, TRX-100
TrialRedline tracks 3 clinical trials sponsored by Traws Pharma, Inc.: 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelNCT07503405 | Influenza A/France/759/2021 (H1N1) virus, TRX-100 | Not yet recruiting | 2026-11Estimated |
| This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate InfluenzaNCT07371650 | Standard of Care (SOC), TRX-100 | Active not recruiting | 2026-12Estimated |
| Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19NCT07157007 | Paxlovid, Ratutrelvir (83-0060), Ratutrelvir (83-0060) non-randomised | Completed | 2026-02-16Actual |
Names as written in the registry records.
NCT07157007 · Traws Pharma, Inc.
Before: Estimated. After: Actual.
Before: 90 participants (planned). After: 93 participants (actual).
Before: Estimated. After: Actual.
Before: Feb 2026. After: 16 Feb 2026.
Before: Recruiting. After: Completed.
Before: Actual. After: Estimated.
Before: 0 participants (actual). After: 105 participants (planned).
Before: Jun 2026. After: Dec 2026.
Before: Withdrawn. After: Active not recruiting.
NCT07157007 · Traws Pharma, Inc.
Before: Dec 2025. After: Feb 2026.
NCT07157007 · Traws Pharma, Inc.
Before: Not yet recruiting. After: Recruiting.